Literature DB >> 15385634

Type 2 diabetes mellitus in children and adolescents--the beginning of a renal catastrophe?

Wieland Kiess, Antje Böttner, Susann Blüher, Klemens Raile, Angela Galler, Thomas Michael Kapellen.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15385634     DOI： 10.1093/ndt/gfh455

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  8 in total

1.  AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

Authors:  Hans Ludwig Schäfer; Wolfgang Linz; Eugen Falk; Maike Glien; Heiner Glombik; Marcus Korn; Wolfgang Wendler; Andreas W Herling; Hartmut Rütten
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

Review 2.  Nephropathy in youth and young adults with type 2 diabetes.

Authors:  Carolina Solis-Herrera; Curtis L Triplitt; Jane L Lynch
Journal:  Curr Diab Rep       Date:  2014-02       Impact factor: 4.810

Review 3.  Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease.

Authors:  Petter Bjornstad; David Z Cherney
Journal:  Curr Diab Rep       Date:  2018-03-19       Impact factor: 4.810

Review 4.  Diabetic nephropathy in children and adolescents.

Authors:  Radovan Bogdanović
Journal:  Pediatr Nephrol       Date:  2007-10-17       Impact factor: 3.714

Review 5.  Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies.

Authors:  Petter Bjornstad; David Z Cherney; David M Maahs; Kristen J Nadeau
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

6.  Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial.

Authors:  Petter Bjornstad; Edward Nehus; Laure El Ghormli; Fida Bacha; Ingrid M Libman; Siripoom McKay; Steven M Willi; Lori Laffel; Silva Arslanian; Kristen J Nadeau
Journal:  Am J Kidney Dis       Date:  2017-11-20       Impact factor: 8.860

7.  Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

Authors:  Mukul R Jain; Suresh R Giri; Chitrang Trivedi; Bibhuti Bhoi; Akshyaya Rath; Geeta Vanage; Purvi Vyas; Ramchandra Ranvir; Pankaj R Patel
Journal:  Pharmacol Res Perspect       Date:  2015-05-04

Review 8.  Emerging global epidemic of obesity: the renal perspective.

Authors:  Anil Kumar Saxena
Journal:  Ann Saudi Med       Date:  2006 Jul-Aug       Impact factor: 1.526
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.